EN DE
Watch Genoway for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Genoway (ALGEN) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Genoway stock €1.47, price €1.98, that is 25.6% below the price, quality 27 out of 100. Rating: overvalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR0004053510

G Genoway logo Thin data Nov 3, 2026

Genoway

ALGEN · PA
Expensive, weak quality

Our calculation puts a fair price 26% below what the stock costs today.

Low debt
Expensive Growth (revenue 5y +13.7 %/yr in EUR)
Loss over the last twelve months · -8.5% net margin (TTM) · fiscal year 2025 4.4%
Mixed vs. peers (5/11)
Revenue last quarter 12% below a year ago.
Fair value €1.47 · Overvalued
Quality 27/100
Negative free cash flow
Narrow moat 16/100 · thin data
Thin data
Watch Genoway for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€4.80 €1.92 Fair Value €1.47 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range €1.92 – €4.80 · fair‑value band €1.24 – €1.75 · the €1.98 price screens above the €1.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 3, 2026.

Follow Genoway in your weekly email

Every Wednesday you see whether Genoway is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide.

Show moreShow less

It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines.

The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines. It serves pharmaceutical and life science companies, and academic institutes.

The company was incorporated in 1999 and is based in Lyon, France.

Stock analysis

Genoway (ALGEN) currently trades at €1.98, while our model-based Fair Value estimate is €1.47, 26% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of €2.60 per share, and 3 of the 10 models we run sit above the €1.98 price.

Bear case: the Asset-Based group reads lowest at €0.2000, and 7 of the 10 models stay below the price. Data coverage for this calculation is low.

Scenario range: €1.24 (bear) to €1.75 (bull), the price of €1.98 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Genoway reported revenue of €21.0M in FY2025 versus €14.0M in FY2021, a compound +10.6%/yr. Reported net income was €928K in FY2025.

Key figures

Market cap €24.4M Micro · P/S ratio 1.05 · EPS (TTM) €−0.1500 · Net margin 4.4% · Return on equity −10.4% · Return on assets (EBIT) 0.5% (5-year average) · Operating margin −26.4% · Revenue (TTM) €24.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).

What moves the price

The share trades about 29% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −26%, ALGEN screens richer than that median.

Fair Value models

Bear €1.24 Fair Value €1.47 Bull €1.75
Price €1.98 · Downside -25.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income €1.50 €1.47 €1.52 71
Growth-Adj P/E €0.9400 €1.35 €1.75 67
EV/EBITDA €2.40 €3.55 €4.71 66
All 11 models by family
Earnings-Based
Graham-Dodd €0.5100 €2.12 €2.89 64
Lynch FV €0.5300 €0.7600 €0.9900 61
PEG = 1.0 €0.5300 €0.7600 €0.9900 57
Multiples
P/E Multiple €1.24 €1.65 €2.07 63
P/S Multiple €0.9600 €1.28 €1.60 58
P/B Multiple €2.99 €3.99 €4.98 55
EV/EBIT n/a n/a €0.0800 61
EV/EBITDA €2.40 €3.55 €4.71 66
Asset-Based
NCAV (Graham) €0.1300 €0.2000 €0.2600 54
Economic Profit
Residual Income €1.50 €1.47 €1.52 71
Growth Earnings
Growth-Adj P/E €0.9400 €1.35 €1.75 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 30
How much profit the company makes from its sales and capital
Quality Growth 43
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 22
Does it invest with discipline instead of growing at any price?
Low Volatility 72
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 11
Distance to the 52-week high, does not count
New shares 45
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−5.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Start year 2020 (pandemic). Over 10 years: +7.5% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−17.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−35% → 3%

ALGEN screens overvalued: fair value 26% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Genoway with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −25.6% · Above median
Profitability
Return on assets 2.1% · Above median
Net margin (12 months) −8.5% · Below median
Operating margin (12 months) −26.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −12.4% · Bottom 25%
Balance sheet
Debt / equity 0.50× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.98× · Cheapest 25%
P/S (12 months) 0.99× · Cheapest 25%
EV/EBITDA 17.5× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)75 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs ALGEN
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs ALGEN
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs ALGEN
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs ALGEN
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs ALGEN
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs ALGEN
argenx SE ARGX $927.21 $908.40 −2% vs ALGEN
CSL Limited CSL A$200.77 A$183.04 −9% vs ALGEN
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs ALGEN
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs ALGEN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genoway: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Genoway Fair Value". https://www.fairvalue-calculator.com/stock/ALGEN

Frequently asked questions

Is Genoway (ALGEN) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of €1.47 versus a price of €1.98, about 26% lower (overvalued).
What is the fair value of ALGEN?
Our model-based fair value for Genoway is €1.47 (as of Nov 3, 2026), built from audited fundamentals. The current price: €1.98.
What is the quality score of ALGEN?
Genoway has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genoway (ALGEN)?
Our model-based price target is the fair value of €1.47 (as of Nov 3, 2026) from 11 valuation models. Cautious scenario €1.24, optimistic scenario €1.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Genoway stock forecast for 2026?
Our models put fair value at €1.47, about 26% lower versus a price of €1.98 (overvalued). Cautious scenario €1.24, optimistic scenario €1.75. The calculation is refreshed regularly with new filings.
What is the revenue of Genoway (ALGEN)?
Genoway reported trailing-twelve-month revenue of about €24.6M (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Genoway (ALGEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genoway it is €1.47 per share (as of Nov 3, 2026), against a price of €1.98. It is the blended result of 11 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Genoway stock overvalued or undervalued in 2026?
As of Nov 3, 2026, ALGEN trades above its calculated fair value: price €1.98, fair value €1.47, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALGEN?
No. The price is what the market pays today (€1.98); the fair value is what the company's own numbers justify (€1.47). For Genoway the two are €0.5050 per share apart. That gap is exactly why we show both numbers side by side.
How much is Genoway worth?
The market values Genoway at about €24.4M (market capitalisation, as of Nov 3, 2026). Per share that is €1.98; our models calculate a fair value of €1.47 per share.
What do the bullish and bearish scenarios say about ALGEN?
Our models span a range for Genoway: cautious scenario €1.24, base €1.47, optimistic €1.75 per share (as of Nov 3, 2026, price €1.98). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genoway (ALGEN)?
Balance-sheet figures for Genoway (as of Nov 3, 2026): return on equity −10.4%, debt of 0.50 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is ALGEN from its 52-week high?
Genoway trades at €1.98, about 29% below its 52-week high of €2.77 and 3% above the low of €1.92 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €1.47 is for.
Which stocks are comparable to Genoway?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genoway stock attractive at the current price?
The data as of Nov 3, 2026: price €1.98, calculated fair value €1.47 (−26%), Quality Score 27/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALGEN calculated?
We run Genoway through 11 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €1.47 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Genoway itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genoway (ALGEN)?
The closing price on Nov 6, 2026 was €1.98. Our model-based fair value is €1.47, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genoway right now?
The price sits above even our optimistic bull case (€1.75). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Genoway

How large is the market capitalisation of Genoway (ALGEN)?
The market capitalisation of Genoway is €24.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genoway (ALGEN)?
The price-to-sales ratio of Genoway is 1.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genoway (ALGEN)?
Earnings per share at Genoway are €−0.1500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Genoway (ALGEN)?
The net margin of Genoway is 4.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genoway (ALGEN)?
The return on equity (ROE) of Genoway is −10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genoway (ALGEN)?
On an EBIT basis the return on assets of Genoway is 0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genoway (ALGEN)?
The operating margin of Genoway is −26.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genoway (ALGEN)?
Revenue at Genoway is growing −12.4% versus a year earlier (3y avg +7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genoway (ALGEN) generate?
The free cash flow of Genoway is −€12.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Genoway (ALGEN) carry?
The net debt of Genoway is €13.2M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Genoway in the live analysis

One click puts Genoway on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.